◎科技日报记者 代小佩 近期，《柳叶刀·糖尿病和内分泌》发布的一项研究引发广泛关注：185个国家中，绝大多数甲状腺癌发 病率持续上升，其中6个国家年均涨幅超过10%。近20年来，15—39岁人群的甲状腺癌患病比例逐年上 升。 此外，年轻人的肥胖问题也值得关注。研究发现，肥胖会增加罹患甲状腺癌的风险。 治疗技术不断进步 多种因素造成患病率升高 甲状腺位于颈前部，形似蝴蝶，是人体重要的内分泌器官。其主要功能是合成和分泌甲状腺激素，调节 体温、心率、胃肠功能等生理活动，堪称"人体发动机"。而甲状腺癌是甲状腺细胞异常增殖形成的肿 瘤，常见于颈部。 近年来，甲状腺癌患病率升高，是多种因素共同作用的结果。北京大学肿瘤医院头颈外科副主任医师宋 韫韬说，从肿瘤大小统计来看，近年来增加最多的是直径小于1厘米的甲状腺微小癌。这类极小的肿 瘤，无论是患者自行触摸还是医生常规检查都难以发现，只能通过超声检查识别。 过去，人们缺乏定期体检的意识和经济能力，很多微小癌未能被检出，也不会被纳入发病统计。"如 今，甲状腺超声检查因操作简单、成本低廉、检出率高，已成为多数体检套餐的标配。这使得大量隐藏 的早期肿瘤浮出水面。"宋韫韬说。 宋韫韬 ...

12月21日，2025"人民好医生 金山茶花计划"总结交流在北京举行。现场汇集了肺癌、肝胆肿瘤、胃 癌、食管癌、乳腺癌、妇科肿瘤、泌尿肿瘤、淋巴瘤、鼻咽癌等领域专家，共同探讨癌症防控新进展， 助力推进癌症防控事业高质量发展。 中国科学院院士、复旦大学附属中山医院名誉院长樊嘉分享了肝胆肿瘤治疗进展。他说，当前肝胆肿瘤 治疗已迈入免疫主导阶段，免疫治疗与靶向、介入治疗的协同联动，显著延长了患者生存期，还为部分 不可切除肿瘤创造根治机会。2025年，国内外权威指南修订、国内多项专家共识出台，进一步推动肝胆 肿瘤诊疗从"经验型"向"循证型"转变。 "得益于精准诊疗的推广、靶向治疗和免疫治疗的应用等，肺癌患者的生存期和生活质量得到了有效延 长和提升。"广东省人民医院首席专家、广东省肺癌研究所名誉所长吴一龙介绍肺癌领域学术科研创新 进展："近年来，SCLC（小细胞肺癌）领域迎来突破性变革，全新的T细胞抗体激活类药物，在SCLC 二线治疗中效果显著，为临床提供了新的治疗范式；在NSCLC（非小细胞肺癌）早中期领域，相关研 究显示纳武利尤单抗联合化疗新辅助治疗能有效提升患者5年生存率，多款创新药物及治疗方案的出 现，推动非小 ...

Core Viewpoint - Recent cases of thyroid cancer among public figures have brought renewed attention to thyroid health issues, highlighting the increasing incidence of thyroid cancer globally and in China [1][2]. Group 1: Incidence and Characteristics of Thyroid Cancer - Thyroid cancer is the most common tumor in the endocrine system, with a significant rise in incidence. In China, the incidence rate increased 20 times from 2000 to 2016, with 466,000 new cases reported in 2022 [1][3]. - The overall development of thyroid cancer is slow, particularly for papillary thyroid cancer, which constitutes about 80% of cases. Many patients experience minimal changes over 5-10 years, and lymph node metastasis rates are low [1][2]. - The incidence rate of thyroid cancer among women in China is particularly high, with a rate of 49.4 per 100,000, making it one of the most common cancers among women [3]. Group 2: Treatment Approaches - Surgical intervention remains the primary treatment for thyroid cancer, with a trend towards preserving thyroid function rather than total thyroidectomy for low-risk patients. High-risk patients may require total thyroidectomy [2][4]. - There is ongoing debate regarding the appropriateness of ablation therapy for certain patients, and the decision-making process for surgery is complex, especially for small tumors [5][4]. Group 3: Emerging Therapies and Drug Approvals - Recent advancements in targeted therapies and immunotherapy for high-risk thyroid cancer have shown some promise, although overall efficacy remains suboptimal [6]. - Several new drugs for thyroid cancer have been approved in China since 2022, including broad-spectrum anti-cancer drugs and specific treatments for differentiated thyroid cancer [7][8]. Group 4: Public Perception and Awareness - The term "lazy cancer" is misleading, as it may downplay the seriousness of certain aggressive forms of thyroid cancer. High-risk cases account for 10-20% of all thyroid cancer cases, translating to thousands of new cases annually in China [9].

维立志博-B(09887)涨超3%，截至发稿，涨2.39%，报53.6港元，成交额5125.77万港元。 LBL-034的I/II期临床研究由北京大学人民医院路瑾教授牵头，在全国17家中心开展，研究证实LBL-034 对RRMM患者(包括具有高危特征的难治亚组)表现出良好的安全性和令人振奋的抗肿瘤活性，展现出同 类最佳治疗潜力。 根据弗若斯特沙利文资料显示，截至2024年11月，LBL-034是全球临床进度仅次于强生、中国临床进度 第一的靶向GPRC5D的CD3 T-cell engager。2024年10月LBL-034获得FDA的孤儿药认定(ODD)，用于治 疗多发性骨髓瘤。 消息面上，维立志博-B发布公告，于2025年12月6日至9日，第67届ASH年会在美国佛罗里达州奥兰多召 开。公司自主研发用于治疗复发性╱难治性多发性骨髓瘤("RRMM")的GPRC5D/CD3双特异性抗体LBL- 034在大会首日第一个进行口头报告。 ...

Financial Data and Key Metrics Changes - The company expects to transition its business model post-Jakafi, aiming for a five-year compound annual growth rate (CAGR) of 15%-20% with multiple products projected to generate over $1 billion in revenue [7][19] - Jakafi sales are anticipated to be preserved with the launch of a once-daily formulation, expected in mid-2026, which could convert 15%-30% of patients to this new version, potentially saving nearly $750 million in sales [9][10] Business Line Data and Key Metrics Changes - The core business, excluding Jakafi, is projected to grow significantly, potentially matching Jakafi's revenue by 2029 [5] - The company has seven late-stage pipeline projects, including targeted treatments for myeloproliferative neoplasms and solid tumor oncology programs [6][19] - Opzelura, a topical treatment, finished the year with approximately $650 million in sales and is expected to grow at a 10% CAGR, potentially doubling by 2030 [27] Market Data and Key Metrics Changes - The U.S. market is seeing a shift from topical corticosteroids to non-steroidal topicals, with Opzelura positioned to benefit from this trend [27] - The company anticipates approval for Opzelura in moderate atopic dermatitis in Europe by mid to late 2026, which could significantly drive growth [28][29] Company Strategy and Development Direction - The company is focused on transitioning to a Hematology/Oncology and Immunology (I&I) company, with a strategy to build a sustainable growth curve post-2029 [5] - Business development efforts will aim to extend the core in hematology, oncology, and immunology [6] - The goal is to have a targeted therapy for every patient with myeloproliferative neoplasms by the end of the decade [23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the pipeline's potential, emphasizing the importance of execution and the favorable positioning of their products in the market [7][26] - The company is aware of competition but believes it has a strong lead in its pipeline, particularly with the 989 mutant CalR antibody [26][19] Other Important Information - The company is preparing for the U.S. submission of povorcitinib in early 2026, with expectations of a launch by late 2026 or early 2027 [42] - The market for hidradenitis suppurativa (HS) is estimated to have around 5 million eligible patients, with the potential for povorcitinib to capture a significant share [44] Q&A Session Summary Question: What is the expected growth for Jakafi and its new formulation? - The once-daily formulation is expected to launch in mid-2026, with a potential conversion of 15%-30% of patients, preserving significant sales [9][10] Question: Can you elaborate on the 989 mutant CalR antibody and its significance? - The 989 antibody has shown promising results in normalizing platelet counts in patients with essential thrombocythemia and is expected to expand into myelofibrosis [14][15] Question: What is the growth outlook for Opzelura? - Opzelura is projected to grow at a 10% CAGR, with significant contributions from increased market penetration and potential new indications [27][28] Question: How does the company plan to address competition in the market? - The company acknowledges competition but believes its strong data and extensive prescriber base will help maintain its market position [36][26] Question: What are the timelines for upcoming submissions and approvals? - The company plans to submit for U.S. approval of povorcitinib in early 2026, with potential approval by late 2026 or early 2027 [42]

Core Viewpoint - The company emphasizes the importance of innovation in drug development for oncology, autoimmune diseases, and neurobiology, highlighting unmet clinical needs and market demand in these areas [1] Group 1: Oncology - Oncology remains a key focus in innovative drug development, with increasing resistance leading to ongoing breakthroughs in immunotherapy, targeted therapy, and personalized medicine [1] - There is a persistent unmet clinical demand in the oncology sector, indicating potential investment opportunities [1] Group 2: Autoimmune Diseases - Autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease are significant areas of interest for biopharmaceutical companies [1] - These diseases predominantly affect the younger workforce, and there is a high demand for effective treatments due to poor treatment outcomes and medication adherence [1] Group 3: Neurobiology - Neurodegenerative diseases like Alzheimer's, Parkinson's, and diabetic neuropathy are gaining attention from global pharmaceutical companies and research institutions [1] - The aging global population is contributing to a rapid increase in the number of patients with neurodegenerative diseases, creating substantial market demand [1] Group 4: Company Performance - For the period from January to September 2025, the company reported revenue of 510 million yuan, a year-on-year decrease of 29.33% [1] - The net profit attributable to the parent company was 6 million yuan, reflecting a significant year-on-year decline of 95.68% [1] Group 5: Drug Development Pipeline - The company has established multiple self-developed drug pipelines in neurobiology, autoimmune diseases, and oncology [1] - It has obtained three IND approvals for Class I new drugs and ten IND approvals for Class II new drugs, indicating progress in its drug development efforts [1]

Core Insights - China's international position in the innovative drug sector is rapidly rising, particularly in the field of targeted drugs represented by Antibody-Drug Conjugates (ADCs), which are becoming the main force in overseas markets [1][2] Group 1: Industry Developments - The 8th Precision Medicine Conference highlighted significant advancements in targeted drug research, with top experts presenting their latest findings [1] - Over the past two decades, the U.S. has dominated the biopharmaceutical sector, but China's innovative drugs have made substantial breakthroughs, narrowing the gap with the U.S. [1][4] - By 2025, Chinese companies are expected to account for half of the INDs approved by the U.S. FDA, with transaction values exceeding $100 billion, and ADCs representing nearly half of the top 20 outbound products from China [1][5] Group 2: Targeted Drug Characteristics - Targeted drugs are designed to precisely identify and act on specific disease-related targets, offering higher treatment selectivity and reduced side effects compared to traditional chemotherapy [2][6] - New treatment modalities, including gene therapy, cell therapy, vaccines, and various ADC models, are emerging as alternatives to traditional targeted drugs [4][6] Group 3: Market Trends - The proportion of external procurement pipelines from Chinese companies by multinational pharmaceutical companies has increased from 10% in 2020 to 29% in 2024 [5] - The primary method for Chinese innovative drugs entering international markets is through licensing agreements, allowing companies to monetize their research while enabling partners to commercialize the drugs in specific regions [5] Group 4: Research and Development Challenges - Despite the rapid development of targeted drugs, the discovery of new targets has become increasingly challenging, leading to a focus on new mechanisms and functions of existing targets [6][7] - The high cost of targeted drugs and the frequent occurrence of drug resistance present significant challenges for patients [6][7] Group 5: Policy and Accessibility - Encouraging more companies to invest in innovative drug development is essential, alongside ensuring reasonable pricing and sales strategies to support ongoing research [7] - The integration of innovative drugs into medical insurance directories has shown effectiveness in making treatments more accessible to patients [7]

现在，瑞士苏黎世联邦理工学院研究团队研发出一种微型机器人，它能在血管中"逆流而上"精确导航。 动物实验中，团队在猪体内和绵羊的脑脊液中验证了系统的有效性，这为未来治疗神经系统等多种疾病提供了新思路。 据 科技日报， 医学界长期以来一直致力于开发能精准地"定点送药"的微型机器人技术，以实现靶向治疗。 相关成果发表于新一期《科学》杂志。 ...

Core Viewpoint - The research team from ETH Zurich has developed a micro-robot capable of precise navigation in blood vessels, which could lead to advancements in targeted therapies for various diseases, particularly in the nervous system [1] Group 1: Technology Development - The micro-robot technology focuses on "targeted drug delivery" through precise navigation [1] - The ability of the micro-robot to navigate "upstream" in blood vessels represents a significant advancement in medical technology [1] Group 2: Research Validation - The effectiveness of the micro-robot was validated through animal experiments conducted in pigs and in the cerebrospinal fluid of sheep [1] - The results of this research have been published in a recent issue of the journal "Science," indicating peer-reviewed validation [1]

Core Viewpoint - The research team from ETH Zurich has developed a micro-robot capable of precise navigation in blood vessels, which could lead to targeted therapies for various diseases, including those affecting the nervous system [1] Group 1: Technology Development - The micro-robot technology focuses on "targeted drug delivery" through precise navigation [1] - The ability of the micro-robot to navigate "upstream" in blood vessels represents a significant advancement in medical technology [1] Group 2: Research Validation - The effectiveness of the micro-robot was validated through animal experiments conducted in pigs and in the cerebrospinal fluid of sheep [1] - The results of this research have been published in a recent issue of the journal "Science," indicating peer recognition and validation of the findings [1]